Last reviewed 2026-06-10 · How we verify

Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis — Treatment Landscape & Competitive Intelligence

Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory

Marketed treatment landscape

Approved drugs treating Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer · 1 drug in Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis:

• Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis treatment updates — RSS
• Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis treatment updates — Atom
• Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis treatment updates — JSON

Cite this brief

Drug Landscape (2026). Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moderate-to-severe-ulcerative-colitis-and-perianal-disease-and-fistulizing-disease-and-axial-involvement-and-psoriatic-arthritis-and-atopic-dermatitis-and-hidradenitis-suppurativa-and-psoriasis. Accessed 2026-06-10.

Related

• Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing